Developing a gene therapy pricing and access strategy plan

The Challenge

Our client, an established biopharma company, needed an early go-to-market pricing and access strategy for their haemophilia B gene therapy.

The Approach

Putnam, an Ashfield Advisory company, was asked to determine the therapy’s value and translate that into an acceptable price point.

The team developed a robust value equation based on stakeholder feedback that was aligned to an estimated price with specific payment models. They also put together a detailed action plan to support market access.

The Results

Following Putnam’s recommendations, the client has begun implementing the plan and is preparing to launch the gene therapy at the proposed price point.

Discover more about EmerGENE

EmerGENE is the first multidisciplinary, global network of experts from across Ashfield and Sharp all passionately focused on the success of your cell and gene therapy.

Discover more